New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
08:18 EDTPCYCPharmacyclics reports sNDA for Imbruvica accepted, priority review granted
Pharmacyclics announced that the FDA has accepted for filing its suplemental new drug application to support the review of Imbruvica in the treatment of patients with CLL and SLL who have received at least one prior therapy for a full approval. The target PDUFA date by which the FDA is planning to finalize the review of this application is October 7.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
14:32 EDTPCYCPharmacyclics estimates raised ahead of Q2 report at Goldman
Goldman raised Pharmacyclics' Q2 Imbruvica US sales estimate to $93M from $82M, vs. consensus of $88M and 2014 to $409M from $383M based on IMS data. The firm rates shares a Buy with a $162 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use